Baseline characteristics of lepirudin-treated study patients and control group
Characteristic . | Lepirudin-treated patients . | Control group* . | P . |
|---|---|---|---|
| No. | 91 | 47 | NA |
| Median age, y (range) | 63 (24-86) | 65.5 (24-90) | .798 |
| Male (%) | 49 (53.8) | 23 (48.9) | .584 |
| Median observation period, d | 24.0 | 15.0 | .0123 |
| Field of underlying disease | .983 | ||
| Internal medicine, no. (%) | 40 (44.0) | 22 (47.8) | — |
| Cardiovascular surgery, no. (%) | 12 (13.2) | 5 (10.9) | — |
| Orthopedic surgery, no. (%) | 10 (11.0) | 2 (4.3) | — |
| Traumatology, no. (%) | 3 (3.3) | 1 (2.2) | — |
| Combinations/other, no. (%) | 26 (28.6) | 16 (34.8) | — |
| Median platelet count nadir, × 109/L | 45.5 | 49.0 | .645 |
Characteristic . | Lepirudin-treated patients . | Control group* . | P . |
|---|---|---|---|
| No. | 91 | 47 | NA |
| Median age, y (range) | 63 (24-86) | 65.5 (24-90) | .798 |
| Male (%) | 49 (53.8) | 23 (48.9) | .584 |
| Median observation period, d | 24.0 | 15.0 | .0123 |
| Field of underlying disease | .983 | ||
| Internal medicine, no. (%) | 40 (44.0) | 22 (47.8) | — |
| Cardiovascular surgery, no. (%) | 12 (13.2) | 5 (10.9) | — |
| Orthopedic surgery, no. (%) | 10 (11.0) | 2 (4.3) | — |
| Traumatology, no. (%) | 3 (3.3) | 1 (2.2) | — |
| Combinations/other, no. (%) | 26 (28.6) | 16 (34.8) | — |
| Median platelet count nadir, × 109/L | 45.5 | 49.0 | .645 |
NA indicates not applicable; —, not assessed.
Contemporaneous control group of patients who were not enrolled in the lepirudin studies but who tested positive for HIT antibodies in the same laboratories during the same period of time and fulfilled the same inclusion and exclusion criteria. Data were missing for the age of one control case and for the field of underlying disease of one control case.